Revance Therapeutics Inc  

(Public, NASDAQ:RVNC)   Watch this stock  
Find more results for DANIEL C HERBERT, MD
21.92
-0.12 (-0.54%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.67 - 22.22
52 week 14.02 - 36.49
Open 21.97
Vol / Avg. 39,231.00/155,784.00
Mkt cap 524.71M
P/E     -
Div/yield     -
EPS -3.82
Shares 23.93M
Beta     -
Inst. own 85%
May 11, 2015
Q1 2015 Revance Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 3, 2015
Revance Therapeutics Inc at Cowen Health Care Conference
Mar 2, 2015
Q4 2014 Revance Therapeutics Inc Earnings Call
Mar 2, 2015
Q4 2014 Revance Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -18949.33% -16427.42%
Operating margin -18462.67% -13590.08%
EBITD margin - -13054.57%
Return on average assets -28.40% -58.50%
Return on average equity -31.30% -668.62%
Employees 83 -
CDP Score - -

Address

7555 Gateway Blvd
NEWARK, CA 94560-1152
United States - Map
+1-510-7423400 (Phone)
+1-510-7423401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Revance Therapeutics, Inc. is a United States-based specialty biopharmaceutical company. The Company develops botulinum toxin products for use in aesthetic and therapeutic indications. The Company has developed a platform technology, TransMTS, which enables local, targeted delivery of botulinum toxin and other macromolecules across skin without patches. The Company's investigational product is a topically applied botulinum toxin type A (BoNTA). Its investigational product, RT001 (botulinum toxin type A) Topical Gel, is designed to reduce crow's feet wrinkles by relaxing the muscles around the eye. RT001, a topically applied botulinum toxin type A, is under investigation for the treatment of hyperhidrosis, or excessive sweating.

Officers and directors

Angus C. Russell Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Dan L. Browne Co-Founder, President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Jacob Martin Waugh M.D. Co-Founder, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Lauren P. Silvernail Chief Financial Officer, Executive Vice President of Corporate Development
Age: 56
Bio & Compensation  - Reuters
Arthur P. Bertolino M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Curtis L. Ruegg Ph.D. Executive Vice President of Research and Development
Age: 46
Bio & Compensation  - Reuters
Sharon Hall Vice President of Regulatory Affairs
Bio & Compensation  - Reuters
Jeanie D. Herbert Senior Director of Investor Relations
Bio & Compensation  - Reuters
Phil J. Vickers Director
Age: 55
Bio & Compensation  - Reuters
Bob Byrnes Independent Director
Age: 70
Bio & Compensation  - Reuters